Continue to Short Boston Scientific (BSX)

{"summary": "Author argues Boston Scientific's WATCHMAN device showed worse outcomes than anticoagulation alone in a recent trial, making the stock a short.", "reason": "The author provides a specific asset, a directional thesis, and a fundamental catalyst based on clinical trial results.", "ideas": [{"symbol": "BSX", "direction": "short", "thesis": "The author argues Boston Scientific's flagship WATCHMAN LAAO device, responsible for 10% of company revenue, was found 'not noninferior' to anticoagulation alone in a recent NEJM trial, meaning procedures yield worse outcomes than anticoagulation. Because physicians would avoid exposing patients to procedure risk and more bleeding, the author expects WATCHMAN to be de-prescribed, pressuring BSX revenue and the stock. The cited catalyst is the NEJM publication; no explicit time horizon is given. Main risk implied is that the trial interpretation or clinical adoption may not translate into the expected revenue decline.", "thesis_short": "Short BSX on WATCHMAN trial failure", "quote": "WATCHMAN, their flagship LAAO device, which is responsible for 10% of company revenue was found recently to be “not noninferior” to anticoagulation alone (eg elliquis).", "confidence": 0.75, "sentiment": -0.8, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}